XML 49 R37.htm IDEA: XBRL DOCUMENT v3.23.3
Fair Value Measurements - Additional Information (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Dec. 31, 2022
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]          
Estimated fair value of equity securities $ 34,043   $ 34,043   $ 32,020
Unrealized gain on equity securities 694 $ 3,496 2,023 $ 323  
Vaxcyte, Inc. | Vaxcyte Common Stock          
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]          
Estimated fair value of equity securities 34,000   34,000   $ 32,000
Unrealized gain on equity securities $ 700 $ 3,500 $ 2,000 $ 300  
Vaxcyte, Inc. | Equity Securities | Vaxcyte Common Stock          
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]          
Number of shares held 667,780   667,780   667,780
Fair Value Measurements Recurring          
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]          
Securities held $ 353,029   $ 353,029   $ 330,430